YDES (YD Bio) EBIT: $ Mil (TTM As of Dec. 2025)


YDES YD Bio Ltd YDES
12 GF Score
Price $2.23
! 1 Warning Sign
View Full Analysis

What is YD Bio EBIT?

YD Bio YDES +4.69% 12 EBIT is $ Mil as of Dec. 2025. GuruFocus rates YDES with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

YD Bio's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-8.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. YD Bio's annualized ROC % for the quarter that ended in Dec. 2025 was -194.35%. YD Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,037.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

YD Bio  (NAS:YDES) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

YD Bio's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-10.534 * ( 1 - 0.02% )/( (4.674 + 6.164)/ 2 )
=-10.5318932/5.419
=-194.35 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.841 - 0.697 - ( 0.47 - max(0, 0.753 - 1.397+0.47))
=4.674

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13.779 - 1.607 - ( 6.008 - max(0, 1.644 - 9.67+6.008))
=6.164

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

YD Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.624/( ( (0.084 + max(-0.095, 0)) + (0.068 + max(1.48, 0)) )/ 2 )
=-16.624/( ( 0.084 + 1.548 )/ 2 )
=-16.624/0.816
=-2,037.25 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.101 + 0.374 + 0.166) - (0.697 + 0.039 + 0)
=-0.095

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.167 + 1.88 + 1.07) - (1.607 + 0.03 + 0)
=1.48

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

YD Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/151.953
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

YD Bio EBIT Related Terms

YD Bio EBIT Historical Data

* Premium members only.

The historical data trend for YD Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

YD Bio EBIT Chart

YD Bio Annual Data
Trend Dec23 Dec24 Dec25
EBIT
0.02 -1.39 -8.31

YD Bio Semi-Annual Data
Dec24 Jun25 Dec25
EBIT 0.00 -0.00 -8.31

YDES vs CRBU, ABOS, PRQR: EBIT Comparison

For the Biotechnology subindustry, YD Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

YD Bio EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YD Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where YD Bio's EV-to-EBIT falls into.


YDES
12GF Score
YD Bio Ltd YDES
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

YD Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
YD Bio (YDES) has a EBIT of $ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on YD Bio.
Is YD Bio's EBIT too high?
YD Bio's current EBIT is $ Mil. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's EBIT compare to CRBU and ABOS?
YD Bio's EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on YD Bio. YD Bio's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current EBIT of $ Mil. The current EBIT is $ Mil. YD Bio's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For YD Bio (YDES), the current EBIT is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

YD Bio Business Description

Address No. 3, Xingnan Street, 12th Floor, Nangang District, Taipei City, TWN, 115001
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score

Get the complete analysis for YDES

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.23
Price